Biovica International announced that the company has signed a commercial partnership agreement for the Nordics with Axlab A/S to commercialize the DiviTum®? TKa assay. In the Nordics, some 5,700 women are diagnosed with metastatic breast cancer every year.

The Nordic countries represent some 6% of the total market potential, estimated by number of patients with metastatic breast cancer, for the combined area of Europe Big-5 and the Nordics. Axlab will lead the Nordic market introduction, where the initial focus will be on breast oncologists and decision-makers creating awareness and demand and establishing the test in guidelines.